|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
JPS63501765A
(ja)
|
1985-11-01 |
1988-07-21 |
インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド |
抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
EP0436597B1
(en)
|
1988-09-02 |
1997-04-02 |
Protein Engineering Corporation |
Generation and selection of recombinant varied binding proteins
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
GB8905669D0
(en)
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
EP0585287B1
(en)
|
1990-07-10 |
1999-10-13 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
ATE352612T1
(de)
|
1990-08-29 |
2007-02-15 |
Pharming Intellectual Pty Bv |
Homologe rekombination in säugetier-zellen
|
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
|
EP0575485A1
(en)
|
1991-03-01 |
1993-12-29 |
Dyax Corp. |
Process for the development of binding mini-proteins
|
|
DK0580737T3
(da)
|
1991-04-10 |
2004-11-01 |
Scripps Research Inst |
Heterodimere receptorbiblioteker ved anvendelse af phagemider
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
|
AU701578B2
(en)
|
1992-08-21 |
1999-02-04 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
US5480974A
(en)
|
1993-06-18 |
1996-01-02 |
The Scripps Research Institute |
Antibodies to human C5a receptor
|
|
HUP0600342A3
(en)
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
|
EP2371861B1
(en)
|
2002-01-25 |
2017-08-09 |
Novo Nordisk A/S |
Monoclonal antibodies against extracellular loops of C5aR
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
AU2003290605A1
(en)
|
2002-11-05 |
2004-06-03 |
The Regents Of The University Of Michigan |
Compositions and methods for the diagnosis and treatment of sepsis
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
ES2314383T3
(es)
|
2003-03-17 |
2009-03-16 |
Bayer Healthcare Ag |
Diagnostico y tratamiento terapeuticos para enfermedades asociadas al receptor 5a del componente del complemento (c5ar).
|
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
|
WO2005050199A1
(en)
|
2003-10-31 |
2005-06-02 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g protein- coupled receptor 77 (gpr77)
|
|
WO2005060739A1
(en)
|
2003-12-24 |
2005-07-07 |
G2 Inflammation Pty Ltd |
Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
EP1810035A4
(en)
|
2004-11-10 |
2010-03-17 |
Macrogenics Inc |
GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
|
|
US20100166741A1
(en)
|
2006-07-13 |
2010-07-01 |
Genentech , Inc. |
Altered br-3 binding polypeptides
|
|
EP2061812A4
(en)
|
2006-08-22 |
2010-06-09 |
G2 Inflammation Pty Ltd |
METHOD FOR THE PRODUCTION OF ANTIBODIES
|
|
MX2009001914A
(es)
*
|
2006-08-22 |
2009-03-31 |
G2 Inflammation Pty Ltd |
Anticuerpos anti-c5ar con propiedades mejoradas.
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
WO2009005651A2
(en)
|
2007-06-29 |
2009-01-08 |
The Trustees Of The University Of Pennsylvania |
Complement-mediated thrombophilic assay
|
|
EP2229410A4
(en)
|
2007-12-05 |
2012-07-04 |
Massachusetts Inst Technology |
AGLYCOSYLATED IMMUNOGLOBULIN MUTANES
|
|
EP2254911B1
(en)
*
|
2008-02-20 |
2015-11-25 |
Novo Nordisk A/S |
Humanized anti-c5ar antibodies
|
|
WO2009108931A2
(en)
|
2008-02-28 |
2009-09-03 |
Case Western Reserve University |
Method of treating cancer
|
|
US20180256646A1
(en)
|
2008-03-06 |
2018-09-13 |
Case Western Reserve University |
Compositions and methods for modulating toll like receptor signal
|
|
NZ597259A
(en)
|
2009-06-23 |
2014-04-30 |
Alexion Pharma Inc |
Bispecific antibodies that bind to complement proteins
|
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
EP2327725A1
(en)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
|
ES2751549T3
(es)
|
2009-11-30 |
2020-04-01 |
Janssen Biotech Inc |
Mutantes de anticuerpos Fc con funciones efectoras ablacionadas
|
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
WO2011100477A2
(en)
*
|
2010-02-10 |
2011-08-18 |
Taiga Biotechnologies, Inc. |
Antibodies and processes for preparing the same
|
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
|
RS67768B1
(sr)
|
2010-11-30 |
2026-03-31 |
Chugai Pharmaceutical Co Ltd |
Terapijski agens koji indukuje citotoksičnost
|
|
TWI812066B
(zh)
|
2010-11-30 |
2023-08-11 |
日商中外製藥股份有限公司 |
具有鈣依存性的抗原結合能力之抗體
|
|
US11130801B2
(en)
|
2011-01-13 |
2021-09-28 |
Case Western Reserve University |
Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
|
|
AU2012214643B2
(en)
|
2011-02-07 |
2016-12-15 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides
|
|
AR085302A1
(es)
|
2011-02-24 |
2013-09-18 |
Sanofi Sa |
Metodo de produccion de anticuerpos sialilados
|
|
CN112812184A
(zh)
|
2011-02-25 |
2021-05-18 |
中外制药株式会社 |
FcγRIIb特异性Fc抗体
|
|
SG10201602394QA
(en)
|
2011-03-29 |
2016-05-30 |
Roche Glycart Ag |
Antibody FC Variants
|
|
EP2698431B1
(en)
|
2011-03-30 |
2020-09-09 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
PL2718322T3
(pl)
|
2011-06-06 |
2019-07-31 |
Novo Nordisk A/S |
Lecznicze przeciwciała
|
|
CN109517059B
(zh)
|
2011-06-30 |
2023-03-28 |
中外制药株式会社 |
异源二聚化多肽
|
|
EP2729496B8
(en)
|
2011-07-06 |
2017-10-18 |
Genmab A/S |
Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
|
|
LT2794658T
(lt)
|
2011-12-19 |
2017-05-10 |
Synimmune Gmbh |
Bispecifinė antikūno molekulė
|
|
JP6226752B2
(ja)
|
2012-02-09 |
2017-11-08 |
中外製薬株式会社 |
抗体のＦｃ領域改変体
|
|
WO2013165690A1
(en)
|
2012-04-30 |
2013-11-07 |
Medimmune, Llc |
Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
|
|
EP4310191A3
(en)
|
2012-06-14 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified fc region
|
|
BR112015000167B1
(pt)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
|
|
WO2014012085A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Bispecific asymmetric heterodimers comprising anti-cd3 constructs
|
|
TW202237660A
(zh)
|
2012-08-24 |
2022-10-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
RU2687043C2
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
CN105392803B
(zh)
|
2013-05-08 |
2019-12-06 |
诺和诺德股份有限公司 |
C5aR拮抗剂的用途
|
|
WO2014190441A1
(en)
|
2013-05-31 |
2014-12-04 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
|
AU2014306002B2
(en)
|
2013-08-07 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
|
|
JP6668345B2
(ja)
|
2014-11-21 |
2020-03-18 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
修飾された重鎖定常領域を含む抗体
|
|
KR101860280B1
(ko)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
|
CA2997745A1
(en)
|
2015-09-14 |
2017-03-23 |
Children's Hospital Medical Center |
Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
|
|
CN106957366B
(zh)
|
2016-01-12 |
2022-02-01 |
上海昀怡健康科技发展有限公司 |
一种C5aR抗体及其制备方法和应用
|
|
SG11201900616UA
(en)
|
2016-08-02 |
2019-02-27 |
Visterra Inc |
Engineered polypeptides and uses thereof
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
JP7471819B2
(ja)
|
2016-10-06 |
2024-04-22 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
工程不純物への結合が低下している抗体
|
|
FR3058159B1
(fr)
|
2016-10-28 |
2022-02-25 |
Lab Francais Du Fractionnement |
Variants de polypeptide fc presentant une demi-vie augmentee
|
|
JP7231549B2
(ja)
|
2017-02-06 |
2023-03-01 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
|
|
WO2018183520A1
(en)
|
2017-03-28 |
2018-10-04 |
Lyvgen Biopharma Holdings Limited |
Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
|
|
TWI826364B
(zh)
|
2017-04-03 |
2023-12-21 |
德商因夫萊亞斯有限公司 |
活性抑制劑於發炎性疾病之治療
|
|
US11492415B2
(en)
|
2017-04-07 |
2022-11-08 |
Kookmin University Industry Academy |
Antibody Fc variants for increased blood half-life
|
|
IL270596B2
(en)
|
2017-05-25 |
2026-01-01 |
Bristol Myers Squibb Co |
Antibodies containing heavy constant regions are adapted for use in cancer therapy
|
|
KR20200012907A
(ko)
|
2017-05-25 |
2020-02-05 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체
|
|
CN111328335A
(zh)
|
2017-06-07 |
2020-06-23 |
根马布私人有限公司 |
基于突变igg六聚体的治疗性抗体
|
|
EP3642230A1
(en)
*
|
2017-06-23 |
2020-04-29 |
InflaRx GmbH |
Treatment of inflammatory diseases with inhibitors of c5a activity
|
|
AU2018359237A1
(en)
|
2017-10-31 |
2020-04-30 |
Chemocentryx, Inc. |
C5aR inhibitor reduction of urinary sCD163
|
|
JP7774283B2
(ja)
|
2017-12-19 |
2025-11-21 |
ザ ロックフェラー ユニバーシティー |
エフェクター機能を改良したヒトＩｇＧのＦｃ領域改変体
|
|
US20210070860A1
(en)
|
2018-03-21 |
2021-03-11 |
Dana-Farber Cancer Institute, Inc. |
Fc variant compositions and methods of use thereof
|
|
US20200376135A1
(en)
|
2018-10-23 |
2020-12-03 |
Magenta Therapeutics, Inc. |
Fc silenced antibody drug conjugates (adcs) and uses thereof
|
|
EP3887397A1
(en)
|
2018-11-28 |
2021-10-06 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
MA55285A
(fr)
|
2019-03-14 |
2022-01-19 |
Morphosys Ag |
Anticorps ciblant c5ar
|
|
US20220306735A1
(en)
|
2019-08-30 |
2022-09-29 |
University Of Kansas |
Compositions including igg fc mutations and uses thereof
|
|
TWI869528B
(zh)
|
2020-01-13 |
2025-01-11 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
|
WO2021180063A1
(en)
|
2020-03-09 |
2021-09-16 |
I-Mab Biopharma Co., Ltd. |
Methods for detecting and quantifying biological modifications in antibodies
|
|
EP4126222A1
(en)
|
2020-03-27 |
2023-02-08 |
InflaRx GmbH |
Inhibitors of c5a for the treatment of corona virus infection
|
|
AU2022207985A1
(en)
*
|
2021-01-13 |
2023-07-06 |
Visterra, Inc. |
Humanized complement 5a receptor 1 antibodies and methods of use thereof
|
|
CA3236564A1
(en)
|
2021-11-02 |
2023-05-11 |
Visterra, Inc. |
Fc variants with abolished binding to fcgammar and c1q
|